BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 12534284)

  • 1. Influenza neuraminidase inhibitors: structure-based design of a novel inhibitor series.
    Stoll V; Stewart KD; Maring CJ; Muchmore S; Giranda V; Gu YG; Wang G; Chen Y; Sun M; Zhao C; Kennedy AL; Madigan DL; Xu Y; Saldivar A; Kati W; Laver G; Sowin T; Sham HL; Greer J; Kempf D
    Biochemistry; 2003 Jan; 42(3):718-27. PubMed ID: 12534284
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structure-based characterization and optimization of novel hydrophobic binding interactions in a series of pyrrolidine influenza neuraminidase inhibitors.
    Maring CJ; Stoll VS; Zhao C; Sun M; Krueger AC; Stewart KD; Madigan DL; Kati WM; Xu Y; Carrick RJ; Montgomery DA; Kempf-Grote A; Marsh KC; Molla A; Steffy KR; Sham HL; Laver WG; Gu YG; Kempf DJ; Kohlbrenner WE
    J Med Chem; 2005 Jun; 48(12):3980-90. PubMed ID: 15943472
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel aromatic inhibitors of influenza virus neuraminidase make selective interactions with conserved residues and water molecules in the active site.
    Finley JB; Atigadda VR; Duarte F; Zhao JJ; Brouillette WJ; Air GM; Luo M
    J Mol Biol; 1999 Nov; 293(5):1107-19. PubMed ID: 10547289
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structure-activity relationship studies of novel carbocyclic influenza neuraminidase inhibitors.
    Kim CU; Lew W; Williams MA; Wu H; Zhang L; Chen X; Escarpe PA; Mendel DB; Laver WG; Stevens RC
    J Med Chem; 1998 Jul; 41(14):2451-60. PubMed ID: 9651151
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Binding interaction analysis of the active site and its inhibitors for neuraminidase (N1 subtype) of human influenza virus by the integration of molecular docking, FMO calculation and 3D-QSAR CoMFA modeling.
    Zhang Q; Yang J; Liang K; Feng L; Li S; Wan J; Xu X; Yang G; Liu D; Yang S
    J Chem Inf Model; 2008 Sep; 48(9):1802-12. PubMed ID: 18707092
    [TBL] [Abstract][Full Text] [Related]  

  • 6. On the structure-based design of novel inhibitors of H5N1 influenza A virus neuraminidase (NA).
    Mitrasinovic PM
    Biophys Chem; 2009 Mar; 140(1-3):35-8. PubMed ID: 19117662
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design, synthesis, inhibitory activity, and SAR studies of pyrrolidine derivatives as neuraminidase inhibitors.
    Zhang J; Wang Q; Fang H; Xu W; Liu A; Du G
    Bioorg Med Chem; 2007 Apr; 15(7):2749-58. PubMed ID: 17287121
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potent inhibition of influenza sialidase by a benzoic acid containing a 2-pyrrolidinone substituent.
    Atigadda VR; Brouillette WJ; Duarte F; Ali SM; Babu YS; Bantia S; Chand P; Chu N; Montgomery JA; Walsh DA; Sudbeck EA; Finley J; Luo M; Air GM; Laver GW
    J Med Chem; 1999 Jul; 42(13):2332-43. PubMed ID: 10395473
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Syntheses and neuraminidase inhibitory activity of multisubstituted cyclopentane amide derivatives.
    Chand P; Babu YS; Bantia S; Rowland S; Dehghani A; Kotian PL; Hutchison TL; Ali S; Brouillette W; El-Kattan Y; Lin TH
    J Med Chem; 2004 Apr; 47(8):1919-29. PubMed ID: 15055992
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design, synthesis, inhibitory activity, and SAR studies of hydrophobic p-aminosalicylic acid derivatives as neuraminidase inhibitors.
    Zhang J; Wang Q; Fang H; Xu W; Liu A; Du G
    Bioorg Med Chem; 2008 Apr; 16(7):3839-47. PubMed ID: 18304821
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design and synthesis of benzoic acid derivatives as influenza neuraminidase inhibitors using structure-based drug design.
    Chand P; Babu YS; Bantia S; Chu N; Cole LB; Kotian PL; Laver WG; Montgomery JA; Pathak VP; Petty SL; Shrout DP; Walsh DA; Walsh GM
    J Med Chem; 1997 Dec; 40(25):4030-52. PubMed ID: 9406595
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analogue inhibitors by modifying oseltamivir based on the crystal neuraminidase structure for treating drug-resistant H5N1 virus.
    Du QS; Wang SQ; Chou KC
    Biochem Biophys Res Commun; 2007 Oct; 362(2):525-31. PubMed ID: 17707775
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The most potent organophosphorus inhibitors of leucine aminopeptidase. Structure-based design, chemistry, and activity.
    Grembecka J; Mucha A; Cierpicki T; Kafarski P
    J Med Chem; 2003 Jun; 46(13):2641-55. PubMed ID: 12801228
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel potent macrocyclic inhibitors of the hepatitis C virus NS3 protease: use of cyclopentane and cyclopentene P2-motifs.
    Bäck M; Johansson PO; Wångsell F; Thorstensson F; Kvarnström I; Ayesa S; Wähling H; Pelcman M; Jansson K; Lindström S; Wallberg H; Classon B; Rydergård C; Vrang L; Hamelink E; Hallberg A; Rosenquist S; Samuelsson B
    Bioorg Med Chem; 2007 Nov; 15(22):7184-202. PubMed ID: 17845856
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design and synthesis of 6-oxo-1,4,5,6-tetrahydropyrimidine-5-carboxylate derivatives as neuraminidase inhibitors.
    Lou J; Yang X; Rao Z; Qi W; Li J; Wang H; Li Y; Li J; Wang Z; Hu X; Liu P; Hong X
    Eur J Med Chem; 2014 Aug; 83():466-73. PubMed ID: 24992074
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ketones as building blocks for dynamic combinatorial libraries: highly active neuraminidase inhibitors generated via selection pressure of the biological target.
    Hochgürtel M; Biesinger R; Kroth H; Piecha D; Hofmann MW; Krause S; Schaaf O; Nicolau C; Eliseev AV
    J Med Chem; 2003 Jan; 46(3):356-8. PubMed ID: 12540234
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Systematic structure-based design and stereoselective synthesis of novel multisubstituted cyclopentane derivatives with potent antiinfluenza activity.
    Chand P; Kotian PL; Dehghani A; El-Kattan Y; Lin TH; Hutchison TL; Babu YS; Bantia S; Elliott AJ; Montgomery JA
    J Med Chem; 2001 Dec; 44(25):4379-92. PubMed ID: 11728184
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Three-dimensional structure of influenza A N9 neuraminidase and its complex with the inhibitor 2-deoxy 2,3-dehydro-N-acetyl neuraminic acid.
    Bossart-Whitaker P; Carson M; Babu YS; Smith CD; Laver WG; Air GM
    J Mol Biol; 1993 Aug; 232(4):1069-83. PubMed ID: 8371267
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A strategy for theoretical binding constant, Ki, calculations for neuraminidase aromatic inhibitors designed on the basis of the active site structure of influenza virus neuraminidase.
    Jedrzejas MJ; Singh S; Brouillette WJ; Air GM; Luo M
    Proteins; 1995 Oct; 23(2):264-77. PubMed ID: 8592707
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BCX-1812 (RWJ-270201): discovery of a novel, highly potent, orally active, and selective influenza neuraminidase inhibitor through structure-based drug design.
    Babu YS; Chand P; Bantia S; Kotian P; Dehghani A; El-Kattan Y; Lin TH; Hutchison TL; Elliott AJ; Parker CD; Ananth SL; Horn LL; Laver GW; Montgomery JA
    J Med Chem; 2000 Sep; 43(19):3482-6. PubMed ID: 11000002
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.